APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Adeno-Associated Virus (AAV) Gene Therapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Adeno-Associated Virus (AAV) Gene Therapy Market Outlook and Growth Opportunities 2026

Report ID 174484650412 August 2026200 pages

Choose your research edition.

Industry ResearchAdeno-Associated Virus (AAV) Gene Therapy Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Adeno-Associated Virus (AAV) Gene Therapy Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Adeno-Associated Virus (AAV) Gene Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Adeno-Associated Virus (AAV) Gene Therapy Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Adeno-Associated Virus (AAV) Gene Therapy Market Analysis and Forecast 2026-2032186 pages · $4,950 USD

Market perspective

The global Adeno-Associated Virus (AAV) Gene Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Adeno-Associated Virus (AAV) Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Adeno-Associated Virus (AAV) Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Adeno-Associated Virus (AAV) Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Adeno-Associated Virus (AAV) Gene Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Adeno-Associated Virus (AAV) Gene Therapy market include AGC Biologics, StrideBio, SIRION Biotech, Neurophth Biotechnology, Belief BioMed, BiBo Biopharma Engineering Co., LTD., Beihai Kangcheng, PackGene Biotech and Sarepta Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Adeno-Associated Virus (AAV) Gene Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Adeno-Associated Virus (AAV) Gene Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Adeno-Associated Virus (AAV) Gene Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Adeno-Associated Virus (AAV) Gene Therapy market.

Adeno-Associated Virus (AAV) Gene Therapy Segment by Company

AGC Biologics

StrideBio

SIRION Biotech

Neurophth Biotechnology

Belief BioMed

BiBo Biopharma Engineering Co., LTD.

Beihai Kangcheng

PackGene Biotech

Sarepta Therapeutics

Carbon BioSciences

Kelonia Therapeutics

Roche

Remedium Bio

Creative Biolabs

Affinia Therapeutics

Spark Therapeutics

Adeno-Associated Virus (AAV) Gene Therapy Segment by Type

Luxturna

Zolgensma

Others

Adeno-Associated Virus (AAV) Gene Therapy Segment by Application

Central Nervous System Diseases

Ocular Diseases

Liver-directed Diseases

Other Hereditary Diseases

Adeno-Associated Virus (AAV) Gene Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Adeno-Associated Virus (AAV) Gene Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Adeno-Associated Virus (AAV) Gene Therapy key companies, revenue, market share, and recent developments.

3. To split the Adeno-Associated Virus (AAV) Gene Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Adeno-Associated Virus (AAV) Gene Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Adeno-Associated Virus (AAV) Gene Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Adeno-Associated Virus (AAV) Gene Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adeno-Associated Virus (AAV) Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Adeno-Associated Virus (AAV) Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adeno-Associated Virus (AAV) Gene Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Adeno-Associated Virus (AAV) Gene Therapy industry.

Chapter 3: Detailed analysis of Adeno-Associated Virus (AAV) Gene Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Adeno-Associated Virus (AAV) Gene Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Adeno-Associated Virus (AAV) Gene Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Adeno-Associated Virus (AAV) Gene Therapy Industry Trends Table 2. Adeno-Associated Virus (AAV) Gene Therapy Industry Drivers Table 3. Adeno-Associated Virus (AAV) Gene Therapy Industry Opportunities and Challenges Table 4. Adeno-Associated Virus (AAV) Gene Therapy Industry Restraints Table 5. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Company (2021-2026) Table 7. Global Adeno-Associated Virus (AAV) Gene Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Adeno-Associated Virus (AAV) Gene Therapy Key Company Manufacturing Base & Headquarters Table 9. Global Adeno-Associated Virus (AAV) Gene Therapy Company, Product Type & Application Table 10. Global Adeno-Associated Virus (AAV) Gene Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Adeno-Associated Virus (AAV) Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Luxturna Table 15. Significant Companies of Zolgensma Table 16. Significant Companies of Others Table 17. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type (2021-2026) Table 21. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Central Nervous System Diseases Table 23. Significant Companies of Ocular Diseases Table 24. Significant Companies of Liver-directed Diseases Table 25. Significant Companies of Other Hereditary Diseases Table 26. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application (2021-2026) Table 30. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application (2027-2032) Table 31. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Region (2021-2026) Table 34. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Region (2027-2032) Table 36. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value Market Share by Country (2021-2026) Table 39. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value Market Share by Country (2027-2032) Table 41. AGC Biologics Company Information Table 42. AGC Biologics Business Overview Table 43. AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 45. AGC Biologics Recent Development Table 46. StrideBio Company Information Table 47. StrideBio Business Overview Table 48. StrideBio Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. StrideBio Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 50. StrideBio Recent Development Table 51. SIRION Biotech Company Information Table 52. SIRION Biotech Business Overview Table 53. SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 55. SIRION Biotech Recent Development Table 56. Neurophth Biotechnology Company Information Table 57. Neurophth Biotechnology Business Overview Table 58. Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 60. Neurophth Biotechnology Recent Development Table 61. Belief BioMed Company Information Table 62. Belief BioMed Business Overview Table 63. Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 65. Belief BioMed Recent Development Table 66. BiBo Biopharma Engineering Co., LTD. Company Information Table 67. BiBo Biopharma Engineering Co., LTD. Business Overview Table 68. BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 70. BiBo Biopharma Engineering Co., LTD. Recent Development Table 71. Beihai Kangcheng Company Information Table 72. Beihai Kangcheng Business Overview Table 73. Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 75. Beihai Kangcheng Recent Development Table 76. PackGene Biotech Company Information Table 77. PackGene Biotech Business Overview Table 78. PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 80. PackGene Biotech Recent Development Table 81. Sarepta Therapeutics Company Information Table 82. Sarepta Therapeutics Business Overview Table 83. Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 85. Sarepta Therapeutics Recent Development Table 86. Carbon BioSciences Company Information Table 87. Carbon BioSciences Business Overview Table 88. Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 90. Carbon BioSciences Recent Development Table 91. Kelonia Therapeutics Company Information Table 92. Kelonia Therapeutics Business Overview Table 93. Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 95. Kelonia Therapeutics Recent Development Table 96. Roche Company Information Table 97. Roche Business Overview Table 98. Roche Adeno-Associated Virus (AAV) Gene Therapy Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Roche Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 100. Roche Recent Development Table 101. Remedium Bio Company Information Table 102. Remedium Bio Business Overview Table 103. Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 105. Remedium Bio Recent Development Table 106. Creative Biolabs Company Information Table 107. Creative Biolabs Business Overview Table 108. Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 110. Creative Biolabs Recent Development Table 111. Affinia Therapeutics Company Information Table 112. Affinia Therapeutics Business Overview Table 113. Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 115. Affinia Therapeutics Recent Development Table 116. Spark Therapeutics Company Information Table 117. Spark Therapeutics Business Overview Table 118. Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 120. Spark Therapeutics Recent Development Table 121. Research Programs/Design for This Report Table 122. Authors List of This Report Table 123. Secondary Sources Table 124. Primary Sources List of Figures Figure 1. Adeno-Associated Virus (AAV) Gene Therapy Product Image Figure 2. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Adeno-Associated Virus (AAV) Gene Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Luxturna Image Figure 8. Zolgensma Image Figure 9. Others Image Figure 10. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type (2021-2032) Figure 13. Central Nervous System Diseases Image Figure 14. Ocular Diseases Image Figure 15. Liver-directed Diseases Image Figure 16. Other Hereditary Diseases Image Figure 17. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application (2021-2032) Figure 20. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Adeno-Associated Virus (AAV) Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 23. North America Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Adeno-Associated Virus (AAV) Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Adeno-Associated Virus (AAV) Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 29. South America Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Luxturna
  • Zolgensma
  • Others
Applications
  • Central Nervous System Diseases
  • Ocular Diseases
  • Liver-directed Diseases
  • Other Hereditary Diseases
Companies covered
  • AGC Biologics
  • StrideBio
  • SIRION Biotech
  • Neurophth Biotechnology
  • Belief BioMed
  • BiBo Biopharma Engineering Co., LTD.
  • Beihai Kangcheng
  • PackGene Biotech
  • Sarepta Therapeutics
  • Carbon BioSciences
  • Kelonia Therapeutics
  • Roche
  • Remedium Bio
  • Creative Biolabs
  • Affinia Therapeutics
  • Spark Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Adeno-Associated Virus (AAV) Gene Therapy Market Dynamics
  1. 2.1 Adeno-Associated Virus (AAV) Gene Therapy Industry Trends
  2. 2.2 Adeno-Associated Virus (AAV) Gene Therapy Industry Drivers
  3. 2.3 Adeno-Associated Virus (AAV) Gene Therapy Industry Opportunities and Challenges
  4. 2.4 Adeno-Associated Virus (AAV) Gene Therapy Industry Restraints
3 Adeno-Associated Virus (AAV) Gene Therapy Market by Company
  1. 3.1 Global Adeno-Associated Virus (AAV) Gene Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Adeno-Associated Virus (AAV) Gene Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Adeno-Associated Virus (AAV) Gene Therapy Company Ranking (2024-2026)
  4. 3.4 Global Adeno-Associated Virus (AAV) Gene Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global Adeno-Associated Virus (AAV) Gene Therapy Company Product Type and Application
  6. 3.6 Global Adeno-Associated Virus (AAV) Gene Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Adeno-Associated Virus (AAV) Gene Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Adeno-Associated Virus (AAV) Gene Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Adeno-Associated Virus (AAV) Gene Therapy Market by Type
  1. 4.1 Adeno-Associated Virus (AAV) Gene Therapy Type Introduction
  2. 4.1.1 Luxturna
  3. 4.1.2 Zolgensma
  4. 4.1.3 Others
  5. 4.2 Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Type
  6. 4.2.1 Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Type (2021-2032)
  8. 4.2.3 Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type (2021-2032)
5 Adeno-Associated Virus (AAV) Gene Therapy Market by Application
  1. 5.1 Adeno-Associated Virus (AAV) Gene Therapy Application Introduction
  2. 5.1.1 Central Nervous System Diseases
  3. 5.1.2 Ocular Diseases
  4. 5.1.3 Liver-directed Diseases
  5. 5.1.4 Other Hereditary Diseases
  6. 5.2 Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Application
  7. 5.2.1 Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Application (2021-2032)
  9. 5.2.3 Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application (2021-2032)
6 Adeno-Associated Virus (AAV) Gene Therapy Regional Value Analysis
  1. 6.1 Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Adeno-Associated Virus (AAV) Gene Therapy Sales Value (2021-2032)
  7. 6.3.2 North America Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Adeno-Associated Virus (AAV) Gene Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Adeno-Associated Virus (AAV) Gene Therapy Sales Value (2021-2032)
  16. 6.6.2 South America Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Country, 2025 VS 2032
7 Adeno-Associated Virus (AAV) Gene Therapy Country-level Value Analysis
  1. 7.1 Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Adeno-Associated Virus (AAV) Gene Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Adeno-Associated Virus (AAV) Gene Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Adeno-Associated Virus (AAV) Gene Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AGC Biologics
  2. 8.1.1 AGC Biologics Company Information
  3. 8.1.2 AGC Biologics Business Overview
  4. 8.1.3 AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  6. 8.1.5 AGC Biologics Recent Developments
  7. 8.2 StrideBio
  8. 8.2.1 StrideBio Company Information
  9. 8.2.2 StrideBio Business Overview
  10. 8.2.3 StrideBio Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 StrideBio Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  12. 8.2.5 StrideBio Recent Developments
  13. 8.3 SIRION Biotech
  14. 8.3.1 SIRION Biotech Company Information
  15. 8.3.2 SIRION Biotech Business Overview
  16. 8.3.3 SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  18. 8.3.5 SIRION Biotech Recent Developments
  19. 8.4 Neurophth Biotechnology
  20. 8.4.1 Neurophth Biotechnology Company Information
  21. 8.4.2 Neurophth Biotechnology Business Overview
  22. 8.4.3 Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  24. 8.4.5 Neurophth Biotechnology Recent Developments
  25. 8.5 Belief BioMed
  26. 8.5.1 Belief BioMed Company Information
  27. 8.5.2 Belief BioMed Business Overview
  28. 8.5.3 Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  30. 8.5.5 Belief BioMed Recent Developments
  31. 8.6 BiBo Biopharma Engineering Co., LTD.
  32. 8.6.1 BiBo Biopharma Engineering Co., LTD. Company Information
  33. 8.6.2 BiBo Biopharma Engineering Co., LTD. Business Overview
  34. 8.6.3 BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  36. 8.6.5 BiBo Biopharma Engineering Co., LTD. Recent Developments
  37. 8.7 Beihai Kangcheng
  38. 8.7.1 Beihai Kangcheng Company Information
  39. 8.7.2 Beihai Kangcheng Business Overview
  40. 8.7.3 Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  42. 8.7.5 Beihai Kangcheng Recent Developments
  43. 8.8 PackGene Biotech
  44. 8.8.1 PackGene Biotech Company Information
  45. 8.8.2 PackGene Biotech Business Overview
  46. 8.8.3 PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  47. 8.8.4 PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  48. 8.8.5 PackGene Biotech Recent Developments
  49. 8.9 Sarepta Therapeutics
  50. 8.9.1 Sarepta Therapeutics Company Information
  51. 8.9.2 Sarepta Therapeutics Business Overview
  52. 8.9.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  54. 8.9.5 Sarepta Therapeutics Recent Developments
  55. 8.10 Carbon BioSciences
  56. 8.10.1 Carbon BioSciences Company Information
  57. 8.10.2 Carbon BioSciences Business Overview
  58. 8.10.3 Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  60. 8.10.5 Carbon BioSciences Recent Developments
  61. 8.11 Kelonia Therapeutics
  62. 8.11.1 Kelonia Therapeutics Company Information
  63. 8.11.2 Kelonia Therapeutics Business Overview
  64. 8.11.3 Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  66. 8.11.5 Kelonia Therapeutics Recent Developments
  67. 8.12 Roche
  68. 8.12.1 Roche Company Information
  69. 8.12.2 Roche Business Overview
  70. 8.12.3 Roche Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Roche Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  72. 8.12.5 Roche Recent Developments
  73. 8.13 Remedium Bio
  74. 8.13.1 Remedium Bio Company Information
  75. 8.13.2 Remedium Bio Business Overview
  76. 8.13.3 Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  78. 8.13.5 Remedium Bio Recent Developments
  79. 8.14 Creative Biolabs
  80. 8.14.1 Creative Biolabs Company Information
  81. 8.14.2 Creative Biolabs Business Overview
  82. 8.14.3 Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  84. 8.14.5 Creative Biolabs Recent Developments
  85. 8.15 Affinia Therapeutics
  86. 8.15.1 Affinia Therapeutics Company Information
  87. 8.15.2 Affinia Therapeutics Business Overview
  88. 8.15.3 Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  90. 8.15.5 Affinia Therapeutics Recent Developments
  91. 8.16 Spark Therapeutics
  92. 8.16.1 Spark Therapeutics Company Information
  93. 8.16.2 Spark Therapeutics Business Overview
  94. 8.16.3 Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  96. 8.16.5 Spark Therapeutics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst